Transaction · 0001437749-26-029257

JORDEN DAVID EMERSON

JORDEN DAVID EMERSON, CEO, CFO, reported an open-market or private purchase at Nuo Therapeutics, Inc. involving 7984.000000 shares for an estimated $8694.58. Reported holdings after the transaction were 2070000.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market buySEC transaction code PCEO, CFO
AURXNuo Therapeutics, Inc.
Filing timeAug 31
Trade dateAug 28, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
—
Pre-filing
1mo ago1w ago1d ago
Returns since
7d30d90d180d1y

AURX price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
AURX since 2026-08-31Filed 3 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Buy
Code P
Identifier
0001437749-26-029257
Common Stock
Transaction date
Aug 28, 2026
Filed Aug 31, 2026, 02:29 PM · 3d delay
Shares
7.98k sh
$109 per share
Estimated value
$869k
Computed from shares × price
Holdings after
2.06M sh
Direct

Filing warnings

Notes recorded with this filing
1 warning
amended filingThis transaction comes from an amended Form 4 filing.

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Amended Filing Director Buy Direct Ownership
+24score
Filing-only score

+24

Compact filing score computed from stored Form 4 facts. Version v1.

Positive filing signal

This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CEO/CFO

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.08 to $1.10, inclusive. The reporting person undertakes to pr…

Amended filing · 0001437749-26-029257
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

AURX